BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020;21:E662. [PMID: 31963924 DOI: 10.3390/ijms21020662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Shin J, Oh TH, Kim JY, Shim JJ, Lee JL. Efficacy and Safety of the Cudrania tricuspidata Extract on Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Multicenter Study. J Clin Med 2021;10:5323. [PMID: 34830605 DOI: 10.3390/jcm10225323] [Reference Citation Analysis]
2 Lock G, Oelckers M, Clauditz TS, Schrader J. Gastric NET Subtypes: Do We Need An Additional One? Z Gastroenterol 2021;59:255-8. [PMID: 33506449 DOI: 10.1055/a-1348-2727] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tatsuguchi A, Hoshino S, Kawami N, Gudis K, Nomura T, Shimizu A, Iwakiri K. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa. Pathol Res Pract 2020;216:153113. [PMID: 32853950 DOI: 10.1016/j.prp.2020.153113] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741. [PMID: 33975680 DOI: 10.1016/j.bpg.2021.101741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Liu M, Popa EC, Finnerty BM, Fahey TJ 3rd, Zarnegar R. Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms. Curr Gastroenterol Rep 2020;22:50. [PMID: 32797314 DOI: 10.1007/s11894-020-00788-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Rico K, Duan S, Pandey RL, Chen Y, Chakrabarti JT, Starr J, Zavros Y, Else T, Katona BW, Metz DC, Merchant JL. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. BMJ Open Gastroenterol 2021;8:e000765. [PMID: 34750164 DOI: 10.1136/bmjgast-2021-000765] [Reference Citation Analysis]
7 Wang L, Chen W, Lin X, Zhang Z, Wang N, Lv Y, Wang X, Gao Y. Protective Effect of Ultraviolet C Irradiation on the Gastric Mucosa of Rats with Chronic Gastritis Induced by Physicochemical Stimulations. Evid Based Complement Alternat Med 2021;2021:5189797. [PMID: 33815550 DOI: 10.1155/2021/5189797] [Reference Citation Analysis]
8 Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 2021;76:13-21. [PMID: 32718584 DOI: 10.1016/j.therap.2020.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77:865-876. [PMID: 32702178 DOI: 10.1111/his.14220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Couvelard A, Cros J. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs. Virchows Arch 2022. [PMID: 35278097 DOI: 10.1007/s00428-022-03306-7] [Reference Citation Analysis]
11 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021. [PMID: 34018229 DOI: 10.1002/hep.31914] [Reference Citation Analysis]